| 5.32 -0.14 (-2.56%) | 04-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 14.8 |
1-year : | 20.14 |
| Resists | First : | 12.67 |
Second : | 17.25 |
| Pivot price | 14.5 |
|||
| Supports | First : | 5.28 |
Second : | 4.39 |
| MAs | MA(5) : | 13.19 |
MA(20) : | 14.94 |
| MA(100) : | 13.96 |
MA(250) : | 13.93 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 38.3 |
D(3) : | 38.7 |
| RSI | RSI(14): 21.5 |
|||
| 52-week | High : | 31.31 | Low : | 5.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CARA ] has closed below the lower bollinger band by 39.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 138.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.53 - 5.56 | 5.56 - 5.58 |
| Low: | 5.21 - 5.25 | 5.25 - 5.27 |
| Close: | 5.27 - 5.32 | 5.32 - 5.37 |
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Tue, 15 Apr 2025
Cara Therapeutics announces 1-for-3 reverse stock split related to Tvardi merger - Hartford Business Journal
Tue, 15 Apr 2025
Tvardi Therapeutics Closes Merger with Cara Therapeutics - citybiz
Tue, 15 Apr 2025
Cara Therapeutics Completes Merger with Tvardi Therapeutics - TipRanks
Tue, 15 Apr 2025
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics - GlobeNewswire
Mon, 14 Apr 2025
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in - GlobeNewswire
Mon, 14 Apr 2025
Major Transformation: Cara Therapeutics Unveils 1:3 Split Plan Before Tvardi Merger - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 13 (%) |
| Held by Institutions | 24.1 (%) |
| Shares Short | 22 (K) |
| Shares Short P.Month | 22 (K) |
| EPS | -46.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.01 |
| Profit Margin | 0 % |
| Operating Margin | -412.5 % |
| Return on Assets (ttm) | -41.1 % |
| Return on Equity (ttm) | -270.1 % |
| Qtrly Rev. Growth | -51.6 % |
| Gross Profit (p.s.) | -19.25 |
| Sales Per Share | 4.69 |
| EBITDA (p.s.) | -36.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | -1.77 |
| Price to Sales | 1.13 |
| Price to Cash Flow | -0.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|